Resource Library

Choosing electronic patient-reported outcomes (ePRO) offers advantages a paper-based solution can’t match, from data quality to patient compliance.

When engaging CROs, sponsors are increasingly prioritizing performance excellence and replicable operating standards.

Protocol amendments are inevitable, but choosing the right RTSM partner can help you navigate study changes with speed and agility.

With increasing regulatory requirements for the inclusion of patient-reported outcomes in study data, maintaining the status quo in PRO collection can have costly consequences.

As clinical trials grow in complexity, study managers need adaptive, unified RTSM technology to help reduce costs and maintain accurate, real-time study data.

Collecting participant data securely is a critical part of running any clinical trial, whether it is decentralized, in-clinic, or somewhere in between. Medrio EDC and ePRO solutions are important assets that help CROs and sponsors do more with less.

Sponsors can reduce the burden of adopting new hybrid decentralized trial technology by explaining its relevance and taking steps to reduce the cost of change.

Employing eConsent benefits participants, sites, sponsors and CROs. In this article, a Medrio Subject Matter Expert explains how this technology creates important advantages for all clinical trial stakeholders.

Why it is time to rethink the status quo around randomization and supply management in early phase studies?

Participant education is a critical part of informed consent and one that is easy to improve by leveraging established patient education best practices. Medrio CEO Nicole Latimer discusses some of the most successful approaches she has seen in her career: